Gene Therapy Horizons for ADSL Deficiency, June 3rd 2026
- rarebirdsadsl
- Jun 5
- 1 min read
This meeting focused on updates from Dr. Xin about the development of a potential gene therapy for people living with ADSL deficiency, an ultra-rare metabolic disorder affecting approximately 163 individuals worldwide.
Dr. Xin shared progress on an AAV-based gene therapy designed to deliver a working copy of the ADSL gene to the central nervous system, with the goal of reducing or preventing neurological symptoms. Early studies in animals have shown the approach to be safe, and laboratory experiments using patient cells have produced encouraging results.
Key findings included successful production of the ADSL protein in patient-derived cells and a reduction in the buildup of harmful substances associated with the disorder. The research team is also conducting longer-term studies in a mouse model of ADSL deficiency, although those results are still preliminary.
Dr. Xin emphasized that significant funding is still needed to move the therapy forward. An estimated $4 million will be required to complete additional preclinical studies, conduct safety testing in larger animals, manufacture the gene therapy vector, and prepare for future clinical trials.
Families were encouraged to support fundraising efforts and to participate in ongoing NIH natural history studies, either through medical record reviews or in-person visits. This research will help scientists better understand the condition, identify potential biomarkers, and lay the groundwork for future clinical trials.
Comments